Skip to content

Post-market Clinical Follow-up (PMCF) Study of the Infinity-Lock Button System for Acromioclavicular Joint Stabilisation

Post-market Clinical Follow-up (PMCF) Study of the Infinity-Lock™ Button System for Acromioclavicular Joint Stabilisation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05397210
Enrollment
58
Registered
2022-05-31
Start date
2022-09-26
Completion date
2030-01-01
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromioclavicular; Dislocation

Brief summary

This is a Post-market Clinical Follow-up Study. It will verify the long-term safety and performance of the Infinity-Lock Button System (ILBS) when used for acute and chronic dislocations of the Acromioclavicular Joint and used as described by the manufacturer's instructions.

Detailed description

This is a Post-market Clinical Follow-up Study. It will verify the long-term safety and performance of the Infinity-Lock Button System (ILBS) when used for acute and chronic dislocations of the Acromioclavicular Joint and used as described by the manufacturer's instructions. The medical device (ILBS) in this study is already on the market and is manufactured by Xiros Ltd. The ILBS comprises of a polyester flexible tubular tape and a titanium button. The tape is used to secure the joint and the button is used to secure the tape into position. This study will collect data on patients who meet the entry criteria and receive the device; it will recruit patients from several clinical sites. All patients in the study will receive the ILBS, as it is a single armed study. The total length of the study is expected to be 4.5 years; this includes a recruitment period of approximately 18 months and a 3-year follow-up. A total of 58 subjects will be enrolled into the study. Follow up is at 3 months, 6 months, 1,2 and 3 years.

Interventions

DEVICEInfinity-Lock Button System

Infinity-Lock Button System

Sponsors

Xiros Ltd
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient must be 16 years old or above. * Patient is diagnosed with acute or chronic Grade Ill-VI ACJ dislocation. * Patient is willing to participate in the study and have been informed of the nature of the study, agree to its follow-up and have provided written informed consent as approved by the Research Ethics Committee (REC).

Exclusion criteria

. * Known hypersensitivity to implant materials. If the patient is suspected of having any foreign body sensitivity, appropriate tests should be made prior to implantation. * Infections or any other structural or pathological condition of the bone or soft tissue (such as hyperlaxity) that would be expected to impair healing or secure fixation. * Patients unable or unwilling to restrict activities to prescribed levels or follow a rehabilitation programme during the healing period. * Skeletally immature patients are not suited as the Infinity-Lock™ Button System will not elongate with growth. The use of this medical device and placement of hardware or implants must not bridge, disturb or disrupt the growth plate. * Any other conditions or factors which in the opinion of the Investigator may interfere with study conduct.

Design outcomes

Primary

MeasureTime frameDescription
Constant Murley Score (CMS)1 yearThe primary performance endpoint is the change in the CMS from baseline to 1 year after surgery. Minimum score is 0 maximum is 100 with the better functioning shoulders having a greater number of points.
Device Related or Procedure Related Adverse events1 yeardevice-related and/or procedure-related adverse events up to 1 year after surgery.

Secondary

MeasureTime frameDescription
Constant Murley Score (CMS)3 yearsChange from baseline CMS and subscale scores (pain, activities of daily living, strength and ROM) at each timepoint up to 3 years after surgery. Minimum score is 0 maximum is 100 with the better functioning shoulders having a greater number of points.
American Shoulder and Elbow Surgeons Score (ASES)3 yearsChange from baseline American Shoulder and Elbow Surgeons (ASES) Score at each timepoint up to 3 years after surgery. Total score 0-100 ASES points, 0 = worse pain and functional loss/disability.
RAND Short Form 36 (SF-36) V13 yearsChange from baseline RAND Short Form 36 (SF-36) V1 Quality of Life Health Survey at each timepoint up to 3 years after surgery.The RAND SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
Nottingham Clavicle Score (NCS)3 yearsChange from baseline Nottingham Clavicle Score (NCS) at each timepoint up to 3 years after surgery. Maximum score of 100 (fewest difficulties) and a minimum score of 20 (most difficulties)
Ability to perform normal daily work and normal recreational activities3 yearsThis is a subscale of the CMS and is a measurement of how much of the normal daily work or recreational activity the patient is able to perform. The scale is a line which will be marked by the subject, it will be reported as 0-100% with 100% meaning they are able to perform 100% of their normal daily work or recreational activity
coracoclavicular distance1 yearChange from baseline CC distance using the anteroposterior (AP) X-ray (Zanca view) at each timepoint up to 1 year after surgery.
Device-related and/or procedure-related adverse events3 yearsDevice-related and/or procedure-related adverse events up to 3 years after surgery.

Countries

United Kingdom

Contacts

CONTACTLisa Cook
lisa.cook@xiros.co.uk+44 (0) 113 238 7200
CONTACTVikki Adams
vikki.adams@xiros.co.uk07825626018

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026